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  Evidence-based answer
erythromycin has a limited role in 
treating pediatric patients (strength of 
recommendation [sOr]: B, limited-quality, 
patient-oriented evidence). Tegaserod and 
cisapride are the only prokinetic agents 
available for constipated adults (sOr: A, 
consistent, good-quality, patient-oriented 
evidence for tegaserod; sOr: B, for 
cisapride), but cardiovascular risk restricts 
prescribing of both medications.
What is the role of prokinetic 
agents for constipation?
z Evidence summary
Prokinetic agents promote transit of in-
testinal contents by increasing the fre-
quency or strength of small intestine 
contractions. Available prokinetics in-
clude erythromycin and metoclopramide. 
Metoclopramide has been tested only for 
upper gastrointestinal mobility. The only 
randomized controlled trials (RCTs) of 
erythromycin for constipation have been 
conducted in children. Cisapride and tega-
serod have been withdrawn from general 
use because of adverse side effects. The 
TABLE summarizes the available data.
Pediatric constipation:  
Erythromycin helps; watch dosage
A small RCT of 14 children between 4 
and 13 years of age showed that erythro-
mycin improved symptoms of constipa-
tion and decreased laxative use (number 
needed to treat [NNT]=10).1 Two RCTs 
in neonates demonstrated that erythro-
mycin shortened intestinal transit time 
and improved feeding tolerance.2,3 
The erythromycin dose used in these 
studies was lower than the dosage for an-
tibiotic purposes; no adverse effects were 
reported. However, cardiac arrhythmias 
and death have occurred when erythro-
mycin is given to adults and children at 
the usual antibiotic doses.4 
Adult constipation:  
The options are limited
One RCT of cisapride for constipation 
showed that it improved symptoms,5 
whereas another demonstrated no sig-
nificant difference between cisapride and 
placebo in constipation-predominant 
irritable bowel syndrome.6 Reports of 
fatal arrhythmias have prompted restric-
tions on the use of the drug.
In 2 RCTs of tegaserod for consti-
pation, patients exhibited improved ab-
dominal symptoms and increased spon-
taneous bowel movements (NNT=6 for 
2 mg and 5 for 6 mg in the first study; 
NNT=11 for 2 mg and 7 for 6 mg in the 
second study).7,8 A pooled analysis of 
RCTs of tegaserod revealed an increase 
in cardiovascular events, prompting 
withdrawal of the drug from the market 
(number needed to harm=1000).9 Tegas-
erod is available only for emergency and 
investigational use.
Renzapride, a newer prokinetic simi-
lar to cisapride, is under investigation. It 
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is one tenth the strength of cisapride and 
carries a lower potential risk of cardiac 
complications.10 Two small placebo-con-
trolled trials demonstrated improved ab-
dominal pain and stool consistency, but 
only 1 showed statistically significant re-
sults compared with placebo.11,12 
Recommendations
The North American Society for Pediat-
ric Gastroenterology, Hepatology, and 
Nutrition states that the benefits of cis-
apride do not outweigh the risks.13 The 
American College of Gastroenterology’s 
Chronic Constipation Task Force states 
that tegaserod effectively treats chronic 
constipation.14 Neither guideline includes 
recommendations regarding other proki-
netic agents. n
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Prokinetics for constipation: What the research tells us
Drug DEsign (n) DosE ouTcomE nnT
Erythromycin 
estolate1
Crossover 
children 
(14)
20 mg/kg/day 
divided qid
†Constipation 
and laxative use
10
cisapride5 rCT adults 
(69)
5-10 mg tid ü spontaneous 
BM  
† abdominal 
pain
4
cisapride6 rCT adults 
(82)
5-10 mg tid abdominal 
pain and 
constipation, 
drug=placebo 
n/a
Tegaserod7 rCT adults 
(1348)
2 mg or 6 mg bid † Constipation 
ü spontaneous 
BM
6 (2 mg) 
5 (6 mg)
Tegaserod8 rCT adults 
(1264)
2 mg or 6 mg bid † Constipation 
and abdominal 
pain 
11 (2 mg) 
7 (6 mg) 
renzapride11 pilot study adults 
(17)
escalating dose:  
2 mg daily  
to 2 mg bid
† abdominal 
pain and  
bloating
not enough 
information  
to calculate
renzapride12 parallel group adults 
(48)
1, 2, or 4 mg daily ü Colonic transit; 
stool form and 
ease of passage, 
drug=placebo
n/a
BM, bowel movement; n/a, not available; nnT, number needed to treat; rCT, randomized controlled trial.
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